Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 16, 2025 10:05 ET | Source: Boehringer Ingelheim Limited

Boehringer provides update on iclepertin Phase III program in schizophrenia

Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with schizophrenia, showing primary and key secondary endpoints were...